OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WARSAW, Ind., May 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2024.

OrthoPediatrics Corp. Reports First Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance

WARSAW, Ind., April 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, May 7, 2024, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024

WARSAW, Ind., April 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it will attend the 8th Annual International Children's Spine Symposium (ICSS), which will take place April 5th and 6th in Denver, Colorado. The meeting, put on by the Armstrong Children's Orthopedic Alliance, offers a comprehensive program of lectures given by an outstanding, international faculty and cadaver labs centered on the cervical spine, lumbo-sacral junction, neuromonitoring, and various aspects of scoliosis.

OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children's Spine Symposium (ICSS)

WARSAW, Ind., March 26, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference.

OrthoPediatrics Corp. to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Call Start 08:00 January 1, 0000 9:04 AM ET OrthoPediatrics Corp (NASDAQ:KIDS ) Q4 2023 Earnings Conference Call March 07, 2024 08:00 AM ET Company Participants Trip Taylor - Investor Relations David Bailey - President and CEO Fred Hite - Chief Operating Officer and CFO Conference Call Participants Matthew O'Brien - Piper Sandler Rick Wise - Stifel Ryan Zimmerman - BTIG Dave Turkaly - Citizens JMP Samuel Brodovsky - Truist Securities Operator Good morning and welcome to OrthoPediatrics Corporation's Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in listen only mode.

OrthoPediatrics Corp (KIDS) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.

OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates

Record full year 2023 revenue of $148.7 million increased 22% compared to prior year Record full year 2023 revenue of $148.7 million increased 22% compared to prior year

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results

WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has launched a new RESPONSE™ Rib and Pelvic Fixation system to treat children with Early Onset Scoliosis (“EOS”). This represents the company's 71st system to treat orthopedic conditions in pediatric patients.

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

WARSAW, Ind., Feb. 28, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was recently named one of the 2024 Best Places to Work in Indiana. This is the 8th time the Company has been recognized by the annual program created by the Indiana Chamber of Commerce.

OrthoPediatrics Corp. Named One of the 2024 Best Places to Work in Indiana

WARSAW, Ind., Feb. 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2023 financial results on Wednesday, March 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, March 7, 2024, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023, and issued 2024 financial guidance.

OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023

Combined organizations have helped more than 1 million kids Expands Specialty Bracing Division with pediatric orthotic management business  offering leading technology and pediatric care through dedicated clinics Closes $80 million debt financing to support acquisition and future business requirements WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it has acquired Boston Orthotics & Prosthetics (“Boston O&P”), a leader in pediatric orthotic management for over 50 years.

OrthoPediatrics Corp. Announces Acquisition of Boston Orthotics & Prosthetics

OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.

OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing

WARSAW, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced the launch of a new division, focused on non-surgical intervention for pediatric orthopedics. The OrthoPediatrics Specialty Bracing division (“OPSB”) will serve as a flagship house of brands and innovative products that expand the Company's Total Addressable Market by approximately $600 million.

OrthoPediatrics Corp. Announces Launch of Specialty Bracing Division

WARSAW, Ind., Dec. 04, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host educational and networking events at IPOS and its increased support of the event as an Emerald-Level sponsor.

OrthoPediatrics Corp. to Host Educational and Networking Events at 19th Annual International Pediatric Orthopaedic Symposium (IPOS)

OrthoPediatrics Corp (NASDAQ:KIDS ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Trip Taylor - Investor Relations David Bailey - President and Chief Executive Officer Fred Hite - Chief Operating and Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Rick Wise - Stifel Ryan Zimmerman - BTIG Samuel Brodovsky - Truist Securities Operator Good morning, and welcome to the OrthoPediatrics Corporation Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

OrthoPediatrics Corp (KIDS) Q3 2023 Earnings Call Transcript

WARSAW, Ind., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2023.

OrthoPediatrics Corp. Reports Third Quarter 2023 Financial Results

WARSAW, Ind., Nov. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the Company has entered into an exclusive Distribution Agreement with Ora Medical, based in Montreal, to sell Ora Medical's gait trainer, The Levity, a device designed for children with walking difficulties.

OrthoPediatrics Corp. Enters Distribution Agreement with Ora Medical

WARSAW, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the limited release of the Mitchell Ponseti Plus Bar (“MP+”) as part of their Specialty Bracing portfolio for kids with clubfoot. The new MP+ Bar features several innovations from their traditional Bar, which was originally launched in 2004. These enhancements include:

OrthoPediatrics Corp. Launches MP+ Bar for Clubfoot

WARSAW, Ind., Oct. 19, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today it has released the new Pediatric Nailing Platform TIBIA system and successfully completed the first cases in its limited launch. The Company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the system in September 2023.

OrthoPediatrics Corp. Launches Pediatric Nailing Platform | Tibia

WARSAW, Ind., Oct. 17, 2023 (GLOBE NEWSWIRE) --  OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2023 financial results on Monday, November 6, 2023, after the market closes. OrthoPediatrics will host a conference call on Tuesday, November 7, 2023, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Third Quarter 2023 Financial Results on November 7, 2023

OrthoPediatrics (KIDS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in OrthoPediatrics (KIDS): Can Its 8.1% Jump Turn into More Strength?

WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the “Alliance for Pediatric Device Innovation” (APDI), to advice the development and commercialization of medical devices designed for children.

News for OrthoPediatrics Stock (KIDS)